TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Linagliptin's Effect on CD34+ Stem Cells

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults aged 30-70 years~* Diagnosis of type 2 diabetes within the previous 15 years using criteria of the American Diabetes Association~* Currently being treated with 1-2 grams/day of metformin, or insulin or both stably~* Hemoglobin A1c (HbA1C) between 6.5% to 10.0% (both inclusive)~* Body Mass Index (BMI) between 25 and 39.9 kg/m2 (both inclusive)~* Chronic Kidney disease (CKD) Stages 1-3, Creatinine clearance (CrCl) less than 90 and more than 29~Exclusion Criteria:~* Type 1 diabetes~* History of Diabetic Ketoacidosis (DKA) or hyperosmolar nonketotic coma~* Hemoglobinopathies with low hematocrit (Below 28 Units)~* History of pancreatitis~* History of cancer within the past 5 years (except basal cell carcinoma)~* Previous cardiovascular or cerebrovascular event within 6 months of screening or active or clinically significant coronary and/or Peripheral Vascular Disease (PVD)~* Statin use started in the last 3 month~* Current use of oral or injectable anti-diabetic medication other than Metformin and insulin~* Consistent use of steroids within the last 3 months~* Any active wounds, or surgery within the past 3 months~* Inflammatory disease, or the chronic use of anti-inflammatory drugs within the past 3 months~* Untreated hyper/hypothyroidism~* Contraindications to moderate exercise~* Implanted devices that might interact with the tanita scale~* Pre-existing liver disease and/or Alanine aminotransferase (ALT) and Aspartate Aminotransferase (AST) \> 2.5 times Under the Normal Limits (UNL)~* Untreated Systolic blood pressure \> 140 mmHg or diastolic blood pressure\> 90 mmHg~* Serum creatinine levels ≥ 2.0~* CKD Stages 4 and 5 (estimated CrCl \<30 mL/min)~* Triglycerides \> 450 mg/dL~* Known allergies or hypersensitivities to Linagliptin or Dipeptidyl peptidase-4 (DDP-4) inhibitors~* Treatment with cytochrome p450 (CYP 3A4) inhibitors~* Women of child bearing age who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study~* Prisoners or subjects that are involuntarily incarcerated~* Subjects who are compulsorily detained for treatment of either a psychiatric or physical (e.g. infectious disease) illness~* Additionally, patients who are active smokers, patients who are pregnant, nursing women, and post-menopausal women who are on hormone replacement therapy will be excluded.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo 1 pill daily for 12 weeks
- Linagliptin (Type: ACTIVE_COMPARATOR): Linagliptin 5mg once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects aged ≥18 years~* Subjects with suspected or known CAD based on signs and/or (typical or atypical) chest pain who have routine CA without intervention within plus/minus 4 weeks of gadobutrol-enhanced CMRI or subjects at low risk of CAD with / or scheduled to get a CTA for the purpose of exclusion of CAD within plus/minus 6 weeks of gadobutrol-enhanced CMRI~* Willingness to undergo unenhanced wall motion and gadobutrol-enhanced CMRI at stress/rest and gated single photon emission computed tomography (GSPECT, if GSPECT will be a study procedure)~* Women of childbearing potential (e.g. age \< 60y, no history of surgical sterilization or hysterectomy): use of contraception and a negative pregnancy test~* Subjects who are scheduled for / have undergone routine GSPECT or undergo GSPECT as a study procedure at stress and at rest within ± 4 weeks of gadobutrol-enhanced CMRI~Exclusion Criteria:~* Suspected clinical instability or unpredictability of the clinical course during the study period~* Contraindication to the cardiac MRI examination (e.g. inability to hold breath; severe claustrophobia, metallic devices such as pace makers)~* History of severe allergic or anaphylactoid reaction to any allergen including drugs and contrast agents according to the investigator's assessment / judgment~* Estimated glomerular filtration rate (eGFR) value \<30 mL/min/1.73 m\^2 derived from a serum / blood creatinine result within 2 weeks prior to gadobutrol injection. Any subject on hemodialysis or peritoneal dialysis is excluded from enrollment.~* Acute renal insufficiency~* Coronary artery bypass grafting (CABG)~* Acute myocardial infarction (\< 14 days prior to inclusion), unstable angina / acute coronary syndrome, severe congestive heart failure~* Irregular heart rhythm~* Condition that precludes the safe administration of pharmacological stressor according to the respective approved label such as sinus node disease, 2nd or 3rd degree atrioventricular block, obstructive lung disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gadobutrol 0.1 mmol/kg body weight (Type: EXPERIMENTAL): Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress and 0.05 mmol/kg BW at rest via a power injector.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male Japanese and Caucasian subjects~* Age between 20 and 55 years (both inclusive) at the time of signing informed consent~* Body weight of equal to or above 54.0 kg~* Body mass index (BMI) between 20.0 and 25.0 kg/m\^2 (both inclusive)~* Glycosylated haemoglobin A1c (HbA1c) below or equal to 6.0%~* For Japanese subjects only: both parents Japanese~* For Caucasian subjects only: both parents Caucasian~Exclusion Criteria:~* Any clinically significant disease history, in the opinion of the investigator, or systemic or organ disease including: cardiological, pulmonary, gastrointestinal, hepatic, neurologic, renal, genitourinary and endocrine, dermatologic or hematologic diseases~* Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2)~* History of chronic pancreatitis or idiopathic acute pancreatitis~* Calcitonin above or equal to 50 ng/L~* History of alcohol abuse within 1 year from screening, or a positive result in the alcohol breath test, or consumption of more than 21 units of alcohol weekly: 1 unit of alcohol equals approximately 250 mL of beer or lager, or approximately120 mL (one glass) of wine or Japanese sake, or approximately 20 mL of spirits~* Smoking of more than 5 cigarettes (including nicotine substitute products) or the equivalent, per day or unwilling to refrain from smoking whenever required for the trial procedure~* Use of prescription drugs within 3 weeks or 5 times the half-life, whichever is longer, prior to Visit 2 (randomisation), non-prescription drugs within 1 week prior to Visit 2 (randomisation). The use of vitamins, minerals and nutritional supplements, and the occasional use of paracetamol (acetaminophen) or acetylsalicylic acid are permitted

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Semaglutide 0.5 mg (Type: EXPERIMENTAL): Dose-escalation trial
- Semaglutide placebo 0.5 mg (Type: PLACEBO_COMPARATOR): None
- Semaglutide 1.0 mg (Type: EXPERIMENTAL): Dose-escalation trial
- Semaglutide placebo 1.0 mg (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Safety and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients at least 18 years of age with active RA for at least 3 months;~* patients of reproductive potential must be using reliable methods of contraception.~Exclusion Criteria:~* major surgery (including joint surgery) within 8 weeks before entering study or planned major surgery within 6 months after entering study;~* treatment with methotrexate (MTX) within 6 months of entering study;~* patients who have stopped previous MTX treatment due to toxicity or lack of response;~* women who are pregnant or breast-feeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~A subject must meet the following inclusion criteria at screening (visit 1) and at randomization (visit 2) to be considered for enrollment in the study:~* Male or female subjects between the ages of 18 and 40.~* Healthy male or female subjects as determined by medical history, physical examination, and judgment of the investigator.~* Male or female subject who is considered biologically capable of having children must agree to commit to the use of a reliable method of birth control for the duration of the study and for 30 days after early discontinuation. A subject is still biologically capable of having children, even if he or she is using contraceptives or if his or her sexual partner is sterile or using contraceptives.~In addition a subject must meet the following inclusion criteria at randomization (visit 2) to be considered for enrollment in the study. The referred blood and urinalysis tests (inclusion criterion 5) will be performed on a blood and urine sample taken at visit 1:~* Female subjects of childbearing potential with a negative urine pregnancy test prior to study drug administration. Note: this criterion will apply to each vaccination visit and to the last study visit.~* Laboratory blood and urinalysis tests results within the per-protocol normal ranges.~* Able to be contacted by telephone during the study period. Note: this criterion will apply to each study visit.~Exclusion Criteria:~None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): rLP2086 vaccine 60 mcg
- 2 (Type: EXPERIMENTAL): rLP2086 vaccine 120 mcg
- 3 (Type: EXPERIMENTAL): rLP2086 vaccine 200 mcg
- 4 (Type: ACTIVE_COMPARATOR): Tdap vaccine - normal saline - normal saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The OBSTACLE Hypoglycemia Study (MK-0000-158)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with Type 2 Diabetes, of either gender and aged between 18-75 years~* Patients being considered for addition of Sulfonylurea on background of at least one other oral hypoglycemic agent, on a usual visit (screening cum enrolment visit), as per the clinical situation judged by participating physician~* Willing to comply with study requirements~Exclusion Criteria:~* Patients with type 1 Diabetes or gestational Diabetes~* Patients currently on insulin therapy or have received Insulin in last 6 months~* Patients currently on Sulfonylurea therapy or have received Sulfonylureas in last 6 months~* Patients currently on Meglitinides therapy or have received Meglitinides in last 6 months~* Patients initiated on Sulfonylurea monotherapy~* Patient on DPP-4 inhibitors, either as monotherapy or as combination therapy~* Patient is, at the time of signing informed consent, a user of recreational or illicit drugs or has had a recent history (within the last year) of drug or alcohol abuse or dependence.~* Patients for whom it would be impossible to complete the questionnaire for whatever reason, in any feasible form~* Patients who are already participating in a clinical trial or other clinical study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- All participants (Type: None): Participants with type 2 diabetes mellitus (T2DM) who had sulfonylurea treatment added to an on-going regime of oral hypoglycemic agent(s).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. Histologically or cytologically confirmed adenocarcinoma of the prostate that is refractory to hormone therapy and previously treated with a Taxotere®-containing regimen.~2. Documented progression of disease (demonstrating at least one visceral or soft tissue metastatic lesion, including a new lesion). Patients with non-measurable disease must have documented rising prostate-specific antigen (PSA) levels or appearance of new lesion.~3. Surgical or hormone-induced castration~4. Life expectancy \> 2 months~5. Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2~Exclusion criteria~1. Previous treatment with mitoxantrone~2. Previous treatment with \<225 mg/m\^2 cumulative dose of Taxotere (or docetaxel)~3. Prior radiotherapy to ≥ 40% of bone marrow~4. Surgery, radiation, chemotherapy, or other anti-cancer therapy within 4 weeks prior to enrollment in the study~5. Other prior malignancy, except for adequately treated superficial basal cell skin cancer, or any other cancer from which the patient has been disease-free for less than 5 years~6. Known brain or leptomeningeal involvement~7. Other concurrent serious illness or medical conditions~8. Inadequate organ function evidenced by unacceptable laboratory results~The investigator will evaluate whether there are other reasons why a patient may not participate.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mitoxantrone + Prednisone (Type: ACTIVE_COMPARATOR): Mitoxantrone + Prednisone
- Cabazitaxel + Prednisone (Type: EXPERIMENTAL): Cabazitaxel + Prednisone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Introducing Rapid Diagnostic Tests Into the Private Health Sector

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with fever~* uncomplicted malaria~Exclusion Criteria:~* Complicated malaria~* known allergic reactions to Lumartem

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- rapid diagnostic test (Type: ACTIVE_COMPARATOR): Treatment and diagnosis of malaria in drugs hops using rapid diagnostic tests
- Presumptive malaria treatment (Type: NO_INTERVENTION): Presumptive treatment for malaria in drug shops

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Treated with a statin - Fasting LDL-C \>=70mg/dL and triglycerides \<=400mg/dL~Exclusion Criteria:~* Pregnant or breastfeeding females - Cardiovascular or cerebrovascular event or procedures during the past 90 days - Congestive heart failure NYHA class IV - Poorly controlled hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bococizumab 150mg (Type: EXPERIMENTAL): Bococizumab 150mg autoinjector (pre-filled pen)
- Bococizumab 75mg (Type: EXPERIMENTAL): Bococizumab 75mg autoinjector (pre-filled pen)
- Bococizumab 150mg placebo (Type: PLACEBO_COMPARATOR): Bococizumab 150mg placebo autoinjector (pre-filled pen)
- Bococizumab 75mg placebo (Type: PLACEBO_COMPARATOR): Bococizumab 75mg autoinjector (pre-filled pen)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects aged 7-11 years (both inclusive) at the time of signing informed consent~* Tanner stage 1 (including subjects with premature adrenarche) at the time of signing informed consent~* BMI (body mass index) corresponding to above or equal to 30 kg/m\^2 for adults by international cut-off points (Cole et al 2000)1 and BMI below or equal to 45 kg/m\^2 as well as BMI above or equal to 95th percentile for age and gender~Exclusion Criteria:~* Subjects with secondary causes of childhood obesity (i.e., hypothalamic, genetic or endocrine causes)~* Subjects with confirmed bulimia nervosa disorder~* Diagnosis of type 1 diabetes mellitus or type 2 diabetes mellitus as defined by glycosylated haemoglobin (HbA1C) Above or equal to 6.5 %~* History of pancreatitis (acute or chronic)~* Presence of severe co-morbidities as judged by the investigator~* Family or personal history of multiple endocrine neoplasia type 2 (MEN2) or medullary thyroid carcinoma (MTC)~* History of major depressive disorder within 2 years before randomisation

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Liraglutide (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Acupuncture in Patients With Stable Angina Pectoris

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1.Meet the diagnostic criteria of ACC/AHA angina pectoris of coronary heart disease.~2.35 ≤ age ≤ 80 years of age, both male and female.~3.The onset of angina pectoris≥3 months, and the frequency of angina attack≥2 a week.~4.Patients signed the informed consent.~Exclusion Criteria:~1. age≤35 or age≥80~2. Pregnant women or women in lactation or women of child bearing potential plan to conceive in the recent six months.~3. Combined with cardiovascular, digestive, respiratory, urinary, blood, nervous, endocrine system, severe primary disease clinical failed to effectively control the disease.~4. Complicated with mental disorders.~5. allergic constitution or bleeding disorder.~6. Patients accompany with acute coronary syndrome (including acute myocardial infarction, unstable angina), severe arrhythmias ( severe atrioventricular block, ventricular tachycardia, heartbeat influence the flow dynamics in supraventricular tachycardia, heartbeat frequent premature beats especially premature ventricular contractions ), atrial fibrillation, primary cardiomyopathy, valvular heart disease.~7. The blood pressure and blood glucose fail to meet the treatment targets.~8. Cardiovascular disease who had been treated with acupuncture during the previous three months.~9. Currently participating in other clinical trials.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- acupoints on specific meridian (Type: EXPERIMENTAL): Acupuncture plus foundation treatment。 We Select specific acpupoints on the heart and pericardium meridian.
- acupoints on the other meridian (Type: ACTIVE_COMPARATOR): Acupuncture plus foundation treatment。We choose the acupoints on the other meridian。
- sham acupoints (Type: SHAM_COMPARATOR): Acupuncture plus foundation treatment。We use sham acupoints。
- waiting-list (Type: OTHER): wait for the treatment，Only basic treatment, We will not treat the participants until they complete all the observations.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete